La santé en Suisse : le point sur les maladies chroniques : rapport national sur la santé 2015

Le vieillissement de la population va de pair avec une progression constante des maladies chroniques dans notre société. Les modes de vie modernes favorisent l'apparition de ces maladies, notamment par le tabagisme, par le manque d'activité physique et par une alimentation déséquilibrée. Les maladies chroniques somatiques sont aujourd'hui dans la ligne de mire des responsables de la politique de la santé. Elles constituent, avec les maladies chroniques psychiques, dont les conséquences sont multiples, un défi de taille pour notre système de santé et un problème majeur de santé publique. La prise en charge des maladies chroniques requiert une bonne coordination du système de santé. La Confédération et les cantons y travaillent activement en s'engageant par exemple dans le domaine du personnel de santé et de l'organisation des structures de soins. Confédération et cantons contribuent à faire en sorte que les maladies chroniques psychiques ou somatiques deviennent moins fréquentes ou soient traitées suffisamment tôt. Tels sont les objectifs des politiques de promotion de la santé et de prévention des maladies, dont l'importance ira croissant à l'avenir. Le présent rapport national sur la santé donne une vue d'ensemble de la santé dans la population suisse; il met en lumière certains aspects importants des maladies chroniques dans notre pays. Puisse-t-il donner des impulsions nouvelles et aider les acteurs du système suisse de santé à maîtriser ensemble les défis liés à ces maladies.

Impacts of Globalization Processes on the Swiss National Business Elite Community : A Diachronic Analysis of Swiss Large Corporations (1980-2010)

This paper investigates the impacts of globalization processes on the Swiss business elite community during the 1980-2010 period. Switzerland has been characterized in the 20th century by its extraordinary stability and by the strong cohesion of its elite community. To study recent changes, we focus on Switzerland's 110 largest firms' by adopting a diachronic perspective based on three elite cohorts (1980, 2000, and 2010). An analysis of interlocking directorates allows us to describe the decline of the Swiss corporate network. The second analysis focuses on top managers' profiles in terms of education, nationality as well as participation in national community networks that used to reinforce the cultural cohesion of the Swiss elite community, especially the militia army. Our results highlight a slow but profound transformation of top management profiles, characterized by a decline of traditional national elements of legitimacy and the emergence of new "global" elements. The diachronic and combined analysis brings into light the strong cultural changes experienced by the national business elite community.

2015 Update on Acute Adverse Reactions to Gadolinium based Contrast Agents in Cardiovascular MR. Large Multi-National and Multi-Ethnical Population Experience With 37788 Patients From the EuroCMR Registry.

OBJECTIVES: Specifically we aim to demonstrate that the results of our earlier safety data hold true in this much larger multi-national and multi-ethnical population. BACKGROUND: We sought to re-evaluate the frequency, manifestations, and severity of acute adverse reactions associated with administration of several gadolinium- based contrast agents during routine CMR on a European level. METHODS: Multi-centre, multi-national, and multi-ethnical registry with consecutive enrolment of patients in 57 European centres. RESULTS: During the current observation 37,788 doses of Gadolinium based contrast agent were administered to 37,788 patients. The mean dose was 24.7 ml (range 5-80 ml), which is equivalent to 0.123 mmol/kg (range 0.01 - 0.3 mmol/kg). Forty-five acute adverse reactions due to contrast administration occurred (0.12%). Most reactions were classified as mild (43 of 45) according to the American College of Radiology definition. The most frequent complaints following contrast administration were rashes and hives (15 of 45), followed by nausea (10 of 45) and flushes (10 of 45). The event rate ranged from 0.05% (linear non-ionic agent gadodiamide) to 0.42% (linear ionic agent gadobenate dimeglumine). Interestingly, we also found different event rates between the three main indications for CMR ranging from 0.05% (risk stratification in suspected CAD) to 0.22% (viability in known CAD). CONCLUSIONS: The current data indicate that the results of the earlier safety data hold true in this much larger multi-national and multi-ethnical population. Thus, the "off-label" use of Gadolinium based contrast in cardiovascular MR should be regarded as safe concerning the frequency, manifestation and severity of acute events.